Overexpression of TRPC6 in bone marrow stromal cells via a CRISPR-based synergistic activation mediator could decrease brain injury significantly and improve neurofunctional outcomes in a rat model of ischemia/reperfusion (Li W. et al., 2019). Here, TRPC6 is linked to ischemia.